Next Article in Journal
Antibacterial Activity of Juglone against Staphylococcus aureus: From Apparent to Proteomic
Next Article in Special Issue
A New Folding Kinetic Mechanism for Human Transthyretin and the Influence of the Amyloidogenic V30M Mutation
Previous Article in Journal
The Potential for Microalgae as Bioreactors to Produce Pharmaceuticals
Previous Article in Special Issue
The Folding of de Novo Designed Protein DS119 via Molecular Dynamics Simulations

Benzbromarone, Quercetin, and Folic Acid Inhibit Amylin Aggregation

Departamento de Bioquímica y Biología Molecular y Celular, Facultad de Ciencias, Universidad de Zaragoza, Pedro Cerbuna 12, 50009 Zaragoza, Spain
Biocomputation and Complex Systems Physics Institute (BIFI), Joint Unit BIFI-IQFR (CSIC), Mariano Esquillor s/n, Edificio I + D, 50018 Zaragoza, Spain
Institut de Biotecnologia i Biomedicina and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
Aragon Health Research Institute (IIS Aragón), Universidad de Zaragoza, 50009 Zaragoza, Spain
Authors to whom correspondence should be addressed.
Academic Editor: Masatoshi Maki
Int. J. Mol. Sci. 2016, 17(6), 964;
Received: 11 January 2016 / Revised: 8 June 2016 / Accepted: 13 June 2016 / Published: 18 June 2016
(This article belongs to the Collection Protein Folding)
Human Amylin, or islet amyloid polypeptide (hIAPP), is a small hormone secreted by pancreatic β-cells that forms aggregates under insulin deficiency metabolic conditions, and it constitutes a pathological hallmark of type II diabetes mellitus. In type II diabetes patients, amylin is abnormally increased, self-assembled into amyloid aggregates, and ultimately contributes to the apoptotic death of β-cells by mechanisms that are not completely understood. We have screened a library of approved drugs in order to identify inhibitors of amylin aggregation that could be used as tools to investigate the role of amylin aggregation in type II diabetes or as therapeutics in order to reduce β-cell damage. Interestingly, three of the compounds analyzed—benzbromarone, quercetin, and folic acid—are able to slow down amylin fiber formation according to Thioflavin T binding, turbidimetry, and Transmission Electron Microscopy assays. In addition to the in vitro assays, we have tested the effect of these compounds in an amyloid toxicity cell culture model and we have found that one of them, quercetin, has the ability to partly protect cultured pancreatic insulinoma cells from the cytotoxic effect of amylin. Our data suggests that quercetin can contribute to reduce oxidative damage in pancreatic insulinoma β cells by modulating the aggregation propensity of amylin. View Full-Text
Keywords: quercetin; benzbromarone; folic acid; amylin; amyloid; aggregation; type II diabetes quercetin; benzbromarone; folic acid; amylin; amyloid; aggregation; type II diabetes
Show Figures

Figure 1

MDPI and ACS Style

López, L.C.; Varea, O.; Navarro, S.; Carrodeguas, J.A.; Sanchez de Groot, N.; Ventura, S.; Sancho, J. Benzbromarone, Quercetin, and Folic Acid Inhibit Amylin Aggregation. Int. J. Mol. Sci. 2016, 17, 964.

AMA Style

López LC, Varea O, Navarro S, Carrodeguas JA, Sanchez de Groot N, Ventura S, Sancho J. Benzbromarone, Quercetin, and Folic Acid Inhibit Amylin Aggregation. International Journal of Molecular Sciences. 2016; 17(6):964.

Chicago/Turabian Style

López, Laura C., Olga Varea, Susanna Navarro, José A. Carrodeguas, Natalia Sanchez de Groot, Salvador Ventura, and Javier Sancho. 2016. "Benzbromarone, Quercetin, and Folic Acid Inhibit Amylin Aggregation" International Journal of Molecular Sciences 17, no. 6: 964.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop